Page 103 - 22-0424
P. 103

The International Journal of the Royal Society of Thailand
                                                                                         Volume XI - 2019



                        For  pharmacogenomics  to  predict drug  response, there  is several
                Pharmacogenomics tests available for assisted in selection the drug with higher
                responsiveness. For examples, the CYP2C19 genotyping for selection of

                clopidogrel, the IL28 genotyping to select interferon alpha. These tests help
                saving costs, by not giving the drug to those who unlikely to response to the
                drug. Recently, genotyping of NAT2 for adjusting the dosage of Isoniazid is likely
                to be a cost-effective approach to use isoniazid.


                        The service pillar in the NCP Genomics Thailand

                        The service is in the plan is referred to the national service for genomic
                medicine. To implement the national level clinical or public health services based
                on the new technology, sustainability is the most important in the design of the
                service.  The human resource development and technology transfer plan is vital
                for sustainability of this implementation. The health insurance organizations or
                the payers, would need to acquire the capability and understanding of the benefit
                and risk of genomic medicine. The provider would need the reskill and continuous
                professional development (CPD) to update the knowledge for the current
                workforce. Preparation for the health care service providers, payers and the
                general public are the key to generalization of the genomic medicine approach.
                The Ministry of Public Health (MOPH) is the principle organization for
                implementation of this NCP Genomics Thailand (GeTH) based on the cabinet
                approval on 26th March 2019, with Health System Research Institute (HSRI),
                as secretariat. It is imperative for the MOPH and National Health Security

                Office (NHSO) to collaborate with all organizations both public and privates to
                realize the benefit of genomic medicine for Thai population. Sustainability can be
                achieved when the universal health coverage integrated the genomic medicine
                into their program preparation principles, appropriate use of the genomic
                medicine would solve the intractable health problems in Thailand.


















                     Surakameth Mahasirimongkol
                     Sacarin Bunbanjerdsuk                                                          97



                                                                                                  11/7/2565 BE   13:30
       _22-0424(089-102)9.indd   97                                                               11/7/2565 BE   13:30
       _22-0424(089-102)9.indd   97
   98   99   100   101   102   103   104   105   106   107   108